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To the Editor: Numerous lines of experimental evidence
implicate IRS2 in insulin signal transduction in key insulin-
responsive tissues, and the combination of insulin resistance
and pancreatic beta cell failure of homozygous Irs2 knockout
mice is highly reminiscent of both core abnormalities in
human type 2 diabetes [1]. IRS2 is therefore a compelling
candidate gene for involvement in prevalent forms of type 2
diabetes and insulin resistance in humans. Nevertheless,
genetic studies to date in humans suggest that common
polymorphisms found in the IRS2 coding or promoter
regions are not associated with insulin resistance or type 2
diabetes [2–4]. Furthermore, these studies have revealed few
Diabetologia (2009) 52:1208–1211
DOI 10.1007/s00125-009-1345-4
Electronic supplementary material The online version of this article
(doi:10.1007/s00125-009-1345-4) contains supplementary material,
which is available to authorised users.
W. E. Bottomley : I. Barroso (*)
Wellcome Trust Sanger Institute,
Hinxton,
Cambridge CB10 1SA, UK
e-mail: ib1@sanger.ac.uk
M. A. Soos : C. Adams :D. B. Savage : R. K. Semple :
S. O’Rahilly
University of Cambridge Metabolic Research Laboratories,















Department of Endocrinology, University Hospital Lewisham,
London, UK
J. P. Monson
Centre for Endocrinology, William Harvey Research Institute,
St Bartholomew’s and The Royal London Hospitals, QMUL,
London, UK
R. Temple
Elsie Bertram Diabetes Centre,
Norfolk and Norwich University Hospital NHS Trust,
Norwich, UK
Y. Tenenbaum-Rakover
Pediatric Endocrine Unit, Ha’Emek Medical Center,
Afula, Israel
J. Tymms
Diabetes Centre, Royal Albert Edward Infirmary,
Wigan, UK
rare non-synonymous variants, none of which appear to have
a strong impact on insulin sensitivity [5, 6].
We have assembled a large cohort of patients with severe
insulin resistance that is likely to be highly enriched for
monogenic disorders of insulin action. All participants gave
informed consent, and our investigations were carried out
with the approval of the local research ethics committee in
Cambridge, UK. This strategy has previously been validated,
for example, by the finding of a convincing pathogenic
mutation in AKT2 [7], despite a failure to find association
between common genetic variation in AKT2 and metabolic
traits [8]. We have now applied this robust approach to IRS2.
We sequenced the coding region of IRS2 in 161
predominantly Europid (n=114) patients with severe
insulin resistance. Severe insulin resistance was defined as
(1) a fasting insulin level of >150 pmol/l or a peak insulin
level on oral glucose tolerance testing of >1,500 pmol/l in
those without diabetes and a BMI of <30 kg/m2, or (2) an
exogenous insulin requirement of >3 U/kg/day in those
with complete insulin deficiency and a BMI of <30 kg/m2.
Those with partial beta cell decompensation or a BMI of
>30 kg/m2 were included at the investigator’s discretion
based on clinical and biochemical features of insulin
resistance disproportionate to body weight, determined by
reference to sex and BMI-specific 95th percentiles for
plasma insulin from more than 500 non-diabetic volunteers.
Eight rare, novel, non-synonymous variants in the IRS2
gene were identified in eight patients from this cohort
(designated as patients SIR1 to SIR8 in Table 1), four of
whom are Europids. Wherever possible, family members of
probands with non-synonymous variants were studied to
look for co-segregation of the genetic variant with insulin
resistance or diabetes.
In the case of SIR1 (c.233G>A, p.S78N), four of the five
family members studied were found to be heterozygous for
this mutation and had insulin levels commensurate with
their degree of obesity [9] (fasting insulin levels 45–
95 pmol/l, BMI 30–38.8 kg/m2); hence, there was no clear
co-segregation of the mutation with severe insulin resis-
tance in the family (Electronic supplementary material
[ESM] Fig. 1), indicating that the S78N change in IRS2
within this family is either benign, as suggested by
Polyphen (http://genetics.bwh.harvard.edu/pph, accessed 4
March 2008)/SIFT (http://blocks.fhcrc.org/sift/SIFT.html,
accessed 22 December 2008) analysis, or is not the sole
genetic determinant of insulin resistance within the kindred.
The location of serine 78 within the Pleckstrin homology
domain of the protein (ESM Fig. 2) and its strong
evolutionary conservation support the view that a patho-
genic role for this protein-altering variant should not be
entirely discounted on the basis of these genetic data.
Eight members of the Turkish family of SIR3, with five
affected members, were also studied, but only the unaffect-
ed father of the proband was found to carry the same
heterozygous mutation (c.1570A>G, p.I524V). Thus, this
non-synonymous change in IRS2 convincingly fails to co-
segregate with insulin resistance in this family (ESM Fig. 3,
ESM Table 1) and is thus most probably benign.
Of the four available relatives of Ashkenazy proband
SIR4 (c.2485C>T, p.P829S), three were heterozygous for
this variant, two of whom exhibited elevated fasting insulin
levels with respect to 500 non-diabetic volunteers (ESM
Fig. 4). However, incomplete clinical data precluded a
definitive conclusion regarding co-segregation of the
mutation with the phenotype in this family. It is of interest
that this variant was absent in 185 Ashkenazy controls and
that proline 829 is conserved in a diverse range of species,
from Pan troglodytes (chimpanzee) down to Xenopus
tropicalis (Western clawed frog) (ESM Fig. 5).
The non-synonymous variant found in SIR6 (c.2834C>T,
p.S945F) was found to be absent in this patient’s mother,
who presented with a similar but milder syndrome of partial
lipodystrophy. Although the father of SIR6 was unavailable
for study (ESM Fig. 6), this suggests that this variant does
not underlie the observed phenotype.
In a study limited to the parents of SIR8 (ESM Fig. 7),
there appeared to be co-segregation of the non-synonymous
variant (c.3983A>G, p.H1328R) found in the proband with
clinical phenotype, but because this change was also
observed twice on sequencing additional controls, this
variant was deemed to be benign.
Subsequent to our family studies, we also sequenced the
IRS2 gene in 173 Europid controls (mean fasting insulin
30 pmol/l, mean BMI 27.3 kg/m2) to assess possible
enrichment of non-synonymous variants in the patients
with severe insulin resistance relative to insulin-sensitive
controls. In the controls (Table 1), we detected four
non-synonymous heterozygous variants, one of which
(c.3983A>G, p.H1328R) was present in two controls
(control 1 and 4), as well as in proband SIR8. These
findings suggest that there is no significant difference in the
frequency of non-synonymous variants in the IRS2 gene
between the two groups studied, with four non-synonymous
variants being found in each group of Europids (4/114
patients vs 4/173 controls, p=0.54).
Our study has revealed several new non-synonymous
variants in the IRS2 gene in both a cohort of predominately
Europid individuals with severe insulin resistance and in
insulin-sensitive Europid volunteers. Wherever possible, we
have performed co-segregation studies on the available
family members of severely insulin-resistant patients, but
we have found no clear evidence that any of the non-
synonymous variants studied has a fully penetrant patho-
genic effect. Given the difficulty involved in performing
detailed functional evaluation of each variant, we thought to
describe these results in the hope that if others have similar
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data, aggregate data may provide the impetus required to
carry out these additional analyses. However, we cannot
rule out the possibility that some of these variants
contribute to the phenotype of these patients in combination
with environmental or other, unknown, genetic variants.
Sequencing of IRS2 in insulin-sensitive controls demon-
strated that there was no enrichment in the number of non-
synonymous variants among the cases, but because this
study only had 4.85% power (at p=0.05 significance) to
detect the modest differences in frequency observed here,
much larger studies will be required to elucidate the role
of rare IRS2 variants in disease. To obtain nominal levels of
significance (p=0.05), assuming the same proportions of
mutation carriers and non-carriers as those we report here,
the study would need to include at least tenfold more
insulin-sensitive and insulin-resistant participants.
In conclusion, we have identified several novel mutations
in the IRS2 gene, which, despite no clear segregation with
insulin resistance in this study, merit further investigation in
additional cohorts; some variants (e.g. P829S) may yet be
shown to have an effect on insulin sensitivity in humans.
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